Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy

NCT01313208 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01313208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01313208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
May 31, 2013
Enrollment
210 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis